Home / Latest Reports / Gemcitabine Hydrochloride Market

Gemcitabine Hydrochloride Market By Type (Branded, Generic), Application (Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-small Cell Lung Carcinoma), End User (Hospitals, Cancer Centers), Key Players and Regions - Global Industry Analysis & Forecast to 2030

Published On : June 2024 Pages : 145 Category: Pharmaceuticals Report Code : HC0917814

Request Sample Inquiry Before Buying Request for Customization Check Discount

The global Gemcitabine Hydrochloride Market is valued at USD XX billion in 2021 and is projected to reach USD XX billion by the end of 2027, growing at a CAGR of XX% during the period 2022 to 2027.

The report exhibit detail coverage of Gemcitabine Hydrochloride industry and market trends. The report also analyses present and past market values to forecast potential market through the forecast period between 2022-2027. This research study of Gemcitabine Hydrochloride Market involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.

In addition, the report provides insight into main drivers, challenges, opportunities and risk of the market and strategies of suppliers. Key players are profiled as well. Overall, this report covers the historical situation, present status and the future prospects of the global Gemcitabine Hydrochloride Market for 2017-2027.

Crystal Market Research envisions that the span of the Gemcitabine Hydrochloride Market will develop amid the estimated time frame as the Compound Annual Growth Rate boosts significantly. The objective of the market research report is the current status of the market and in accordance classifies it into a few portions. The report takes into consideration the prime market players in every area from over the globe.

Our research study analyses the size of the global market of Gemcitabine Hydrochloride in primary regions such as North America, South America, Middle East & Africa, Asia Pacific and Europe. It also classifies the Gemcitabine Hydrochloride Market by key manufacturers, region, type and application. Furthermore, this study examines in the status of the market, market share, future trends, growth rate, competitive landscape, opportunities, market driving factors and restraints, and challenges.

To stay updated with the latest technology and functions of the industry, Crystal Market Research regularly performs interviews with several industry experts and visits for its expert research analysts. The data sources include but not limited to reports of company’s, international organizations and governments, MMI market surveys, and related industry news.

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2017 to 2027. This report has segmented the Gemcitabine Hydrochloride Market on the basis of type, application, and region:

Competitive Analysis                    

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

  • Accord Healthcare
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Fresenius SE & Co. KGaA
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Ingenus Pharmaceuticals, LLC
  • Cornerstone Pharmaceuticals, Inc.
  • ADC Therapeutics SA
  • Hikma Pharmaceuticals plc
  • Teva Pharmaceutical Industries Ltd.

By Type

  • Branded
  • Generic

By Application

  • Pancreatic Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Non-small Cell Lung Carcinoma (NSCLC)
  • Others

By End User

  • Hospitals
  • Cancer Centers
  • Others

By Region

  • North America (US, Canada)
  • Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
  • South America (Brazil, Mexico, Columbia, Rest of South America)
  • Middle East and Africa (Saudi Arabia, UAE, South Africa, Turkey, Rest of MEA)

Years considered for this report:
Historical Years: 2017-2021
Base Year: 2021
Estimated Year: 2022
Forecast Period: 2022-2027

Some of the key questions answered by the report are:

  • What was the market size in 2017 and forecast from 2022 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Table of Contents

1.     Introduction

1.1.  Report Description

1.2.  Research Methodology

1.2.1.     Data Mining

1.2.2.     Market Modeling and Forecasting

1.2.3.     Data Validation

1.2.4.     Industry Analysis

2.     Market Dashboard

3.     Market Overview

3.1.  Introduction

3.1.1.     Market Definition

3.1.2.     Market Segmentation

3.2.  Market Dynamics

3.2.1.     Drivers

3.2.2.     Restraints

3.2.3.     Opportunities

3.2.4.     Challenges

4.     Gemcitabine Hydrochloride Market, By Type

4.1.  Introduction

4.2.  Gemcitabine Hydrochloride Market Size and Growth Rate By Type (2017-2022)

4.3.  Branded

4.3.1.     Global Branded Market Size and Growth Rate (2017-2022)

4.4.  Generic

4.4.1.     Global Generic Market Size and Growth Rate (2017-2022)

5.     Gemcitabine Hydrochloride Market, By Application

5.1.  Introduction

5.2.  Gemcitabine Hydrochloride Market Size and Growth Rate By Application (2017-2022)

5.3.  Pancreatic Cancer

5.3.1.     Global Pancreatic Cancer Market Size and Growth Rate (2017-2022)

5.4.  Breast Cancer

5.4.1.     Global Breast Cancer Market Size and Growth Rate (2017-2022)

5.5.  Ovarian Cancer

5.5.1.     Global Ovarian Cancer Market Size and Growth Rate (2017-2022)

5.6.  Non-small Cell Lung Carcinoma (NSCLC)

5.6.1.     Global Non-small Cell Lung Carcinoma (NSCLC) Market Size and Growth Rate (2017-2022)

5.7.  Others

5.7.1.     Global Others Market Size and Growth Rate (2017-2022)

6.     Gemcitabine Hydrochloride Market, By End User

6.1.  Introduction

6.2.  Gemcitabine Hydrochloride Market Size and Growth Rate By End User (2017-2022)

6.3.  Hospitals

6.3.1.     Global Hospitals Market Size and Growth Rate (2017-2022)

6.4.  Cancer Centers

6.4.1.     Global Cancer Centers Market Size and Growth Rate (2017-2022)

6.5.  Others

6.5.1.     Global Others Market Size and Growth Rate (2017-2022)

7.     Gemcitabine Hydrochloride Market, By Region

7.1.  Introduction

7.2.  Gemcitabine Hydrochloride Market Size and Growth Rate By Regions

7.2  North America

7.2.1.     North America Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022))

7.2.2.     North America Gemcitabine Hydrochloride Market By Type (2017-2022)

7.2.3.     North America Gemcitabine Hydrochloride Market By Application (2017-2022)

7.2.4.     North America Gemcitabine Hydrochloride Market By End User (2017-2022)

7.2.5.     North America Gemcitabine Hydrochloride Market By Country (2017-2022)

7.2.6.     United States

7.2.6.1.United States Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.2.6.2.United States Gemcitabine Hydrochloride Market By Type (2017-2022)

7.2.6.3.United States Gemcitabine Hydrochloride Market By Application (2017-2022)

7.2.6.4.United States Gemcitabine Hydrochloride Market By End User (2017-2022)

7.2.7.     Canada

7.2.7.1.Canada Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.2.7.2.Canada Gemcitabine Hydrochloride Market By Type (2017-2022)

7.2.7.3.Canada Gemcitabine Hydrochloride Market By Application (2017-2022)

7.2.7.4.Canada Gemcitabine Hydrochloride Market By End User (2017-2022)

7.3  Europe

7.3.1.     Europe Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022))

7.3.2.     Europe Gemcitabine Hydrochloride Market By Type (2017-2022)

7.3.3.     Europe Gemcitabine Hydrochloride Market By Application (2017-2022)

7.3.4.     Europe Gemcitabine Hydrochloride Market By End User (2017-2022)

7.3.5.     Europe Gemcitabine Hydrochloride Market By Country (2017-2022)

7.3.6.     Germany

7.3.6.1.Germany Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.3.6.2.Germany Gemcitabine Hydrochloride Market By Type (2017-2022)

7.3.6.3.Germany Gemcitabine Hydrochloride Market By Application (2017-2022)

7.3.6.4.Germany Gemcitabine Hydrochloride Market By End User (2017-2022)

7.3.7.     France

7.3.7.1.France Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.3.7.2.France Gemcitabine Hydrochloride Market By Type (2017-2022)

7.3.7.3.France Gemcitabine Hydrochloride Market By Application (2017-2022)

7.3.7.4.France Gemcitabine Hydrochloride Market By End User (2017-2022)

7.3.8.     UK

7.3.8.1.UK Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.3.8.2.UK Gemcitabine Hydrochloride Market By Type (2017-2022)

7.3.8.3.UK Gemcitabine Hydrochloride Market By Application (2017-2022)

7.3.8.4.UK Gemcitabine Hydrochloride Market By End User (2017-2022)

7.3.9.     Russia

7.3.9.1.Russia Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.3.9.2.Russia Gemcitabine Hydrochloride Market By Type (2017-2022)

7.3.9.3.Russia Gemcitabine Hydrochloride Market By Application (2017-2022)

7.3.9.4.Russia Gemcitabine Hydrochloride Market By End User (2017-2022)

7.3.10.     Italy

7.3.10.1.Italy Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.3.10.2.Italy Gemcitabine Hydrochloride Market By Type (2017-2022)

7.3.10.3.Italy Gemcitabine Hydrochloride Market By Application (2017-2022)

7.3.10.4.Italy Gemcitabine Hydrochloride Market By End User (2017-2022)

7.3.11.     Rest of Europe

7.3.11.1.Rest of Europe Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.3.11.2.Rest of Europe Gemcitabine Hydrochloride Market By Type (2017-2022)

7.3.11.3.Rest of Europe Gemcitabine Hydrochloride Market By Application (2017-2022)

7.3.11.4.Rest of Europe Gemcitabine Hydrochloride Market By End User (2017-2022)

7.4  Asia-Pacific

7.4.1.     Asia-Pacific Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022))

7.4.2.     Asia-Pacific Gemcitabine Hydrochloride Market By Type (2017-2022)

7.4.3.     Asia-Pacific Gemcitabine Hydrochloride Market By Application (2017-2022)

7.4.4.     Asia-Pacific Gemcitabine Hydrochloride Market By End User (2017-2022)

7.4.5.     Asia-Pacific Gemcitabine Hydrochloride Market By Country (2017-2022)

7.4.6.     China

7.4.6.1.China Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.4.6.2.China Gemcitabine Hydrochloride Market By Type (2017-2022)

7.4.6.3.China Gemcitabine Hydrochloride Market By Application (2017-2022)

7.4.6.4.China Gemcitabine Hydrochloride Market By End User (2017-2022)

7.4.7.     Japan

7.4.7.1.Japan Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.4.7.2.Japan Gemcitabine Hydrochloride Market By Type (2017-2022)

7.4.7.3.Japan Gemcitabine Hydrochloride Market By Application (2017-2022)

7.4.7.4.Japan Gemcitabine Hydrochloride Market By End User (2017-2022)

7.4.8.     Korea

7.4.8.1.Korea Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.4.8.2.Korea Gemcitabine Hydrochloride Market By Type (2017-2022)

7.4.8.3.Korea Gemcitabine Hydrochloride Market By Application (2017-2022)

7.4.8.4.Korea Gemcitabine Hydrochloride Market By End User (2017-2022)

7.4.9.     India

7.4.9.1.India Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.4.9.2.India Gemcitabine Hydrochloride Market By Type (2017-2022)

7.4.9.3.India Gemcitabine Hydrochloride Market By Application (2017-2022)

7.4.9.4.India Gemcitabine Hydrochloride Market By End User (2017-2022)

7.4.10.     Southeast Asia

7.4.10.1.Southeast Asia Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.4.10.2.Southeast Asia Gemcitabine Hydrochloride Market By Type (2017-2022)

7.4.10.3.Southeast Asia Gemcitabine Hydrochloride Market By Application (2017-2022)

7.4.10.4.Southeast Asia Gemcitabine Hydrochloride Market By End User (2017-2022)

7.4.11.     Rest of Asia-Pacific

7.4.11.1.Rest of Asia-Pacific Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.4.11.2.Rest of Asia-Pacific Gemcitabine Hydrochloride Market By Type (2017-2022)

7.4.11.3.Rest of Asia-Pacific Gemcitabine Hydrochloride Market By Application (2017-2022)

7.4.11.4.Rest of Asia-Pacific Gemcitabine Hydrochloride Market By End User (2017-2022)

7.5  South America

7.5.1.     South America Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022))

7.5.2.     South America Gemcitabine Hydrochloride Market By Type (2017-2022)

7.5.3.     South America Gemcitabine Hydrochloride Market By Application (2017-2022)

7.5.4.     South America Gemcitabine Hydrochloride Market By End User (2017-2022)

7.5.5.     South America Gemcitabine Hydrochloride Market By Country (2017-2022)

7.5.6.     Brazil

7.5.6.1.Brazil Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.5.6.2.Brazil Gemcitabine Hydrochloride Market By Type (2017-2022)

7.5.6.3.Brazil Gemcitabine Hydrochloride Market By Application (2017-2022)

7.5.6.4.Brazil Gemcitabine Hydrochloride Market By End User (2017-2022)

7.5.7.     Mexico

7.5.7.1.Mexico Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.5.7.2.Mexico Gemcitabine Hydrochloride Market By Type (2017-2022)

7.5.7.3.Mexico Gemcitabine Hydrochloride Market By Application (2017-2022)

7.5.7.4.Mexico Gemcitabine Hydrochloride Market By End User (2017-2022)

7.5.8.     Columbia

7.5.8.1.Columbia Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.5.8.2.Columbia Gemcitabine Hydrochloride Market By Type (2017-2022)

7.5.8.3.Columbia Gemcitabine Hydrochloride Market By Application (2017-2022)

7.5.8.4.Columbia Gemcitabine Hydrochloride Market By End User (2017-2022)

7.5.9.     Rest of South America

7.5.9.1.Rest of South America Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.5.9.2.Rest of South America Gemcitabine Hydrochloride Market By Type (2017-2022)

7.5.9.3.Rest of South America Gemcitabine Hydrochloride Market By Application (2017-2022)

7.5.9.4.Rest of South America Gemcitabine Hydrochloride Market By End User (2017-2022)

7.6  Middle East and Africa

7.6.1.     Middle East and Africa Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022))

7.6.2.     Middle East and Africa Gemcitabine Hydrochloride Market By Type (2017-2022)

7.6.3.     Middle East and Africa Gemcitabine Hydrochloride Market By Application (2017-2022)

7.6.4.     Middle East and Africa Gemcitabine Hydrochloride Market By End User (2017-2022)

7.6.5.     Middle East and Africa Gemcitabine Hydrochloride Market By Country (2017-2022)

7.6.6.     Saudi Arabia

7.6.6.1.Saudi Arabia Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.6.6.2.Saudi Arabia Gemcitabine Hydrochloride Market By Type (2017-2022)

7.6.6.3.Saudi Arabia Gemcitabine Hydrochloride Market By Application (2017-2022)

7.6.6.4.Saudi Arabia Gemcitabine Hydrochloride Market By End User (2017-2022)

7.6.7.     United Arab Emirates

7.6.7.1.United Arab Emirates Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.6.7.2.United Arab Emirates Gemcitabine Hydrochloride Market By Type (2017-2022)

7.6.7.3.United Arab Emirates Gemcitabine Hydrochloride Market By Application (2017-2022)

7.6.7.4.United Arab Emirates Gemcitabine Hydrochloride Market By End User (2017-2022)

7.6.8.     South Africa

7.6.8.1.South Africa Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.6.8.2.South Africa Gemcitabine Hydrochloride Market By Type (2017-2022)

7.6.8.3.South Africa Gemcitabine Hydrochloride Market By Application (2017-2022)

7.6.8.4.South Africa Gemcitabine Hydrochloride Market By End User (2017-2022)

7.6.9.     Rest of Middle East and Africa

7.6.9.1.Rest of Middle East and Africa Gemcitabine Hydrochloride Market Size and Growth Rate (2017-2022)

7.6.9.2.Rest of Middle East and Africa Gemcitabine Hydrochloride Market By Type (2017-2022)

7.6.9.3.Rest of Middle East and Africa Gemcitabine Hydrochloride Market By Application (2017-2022)

7.6.9.4.Rest of Middle East and Africa Gemcitabine Hydrochloride Market By End User (2017-2022)

8.     Company Profiles

8.1.  Accord Healthcare

8.1.1.     Business Overview

8.1.2.     Service Portfolio

8.1.3.     Strategic Developments

8.1.4.     Financial Overview

8.2.  Dr. Reddy's Laboratories Ltd.

8.2.1.     Business Overview

8.2.2.     Service Portfolio

8.2.3.     Strategic Developments

8.2.4.     Financial Overview

8.3.  Sun Pharmaceutical Industries Ltd.

8.3.1.     Business Overview

8.3.2.     Service Portfolio

8.3.3.     Strategic Developments

8.3.4.     Financial Overview

8.4.  Mylan N.V.

8.4.1.     Business Overview

8.4.2.     Service Portfolio

8.4.3.     Strategic Developments

8.4.4.     Financial Overview

8.5.  Fresenius SE & Co. KGaA

8.5.1.     Business Overview

8.5.2.     Service Portfolio

8.5.3.     Strategic Developments

8.5.4.     Financial Overview

8.6.  Pfizer, Inc.

8.6.1.     Business Overview

8.6.2.     Service Portfolio

8.6.3.     Strategic Developments

8.6.4.     Financial Overview

8.7.  Eli Lilly and Company

8.7.1.     Business Overview

8.7.2.     Service Portfolio

8.7.3.     Strategic Developments

8.7.4.     Financial Overview

8.8.  Ingenus Pharmaceuticals, LLC

8.8.1.     Business Overview

8.8.2.     Service Portfolio

8.8.3.     Strategic Developments

8.8.4.     Financial Overview

8.9.  Cornerstone Pharmaceuticals, Inc.

8.9.1.     Business Overview

8.9.2.     Service Portfolio

8.9.3.     Strategic Developments

8.9.4.     Financial Overview

8.10.  ADC Therapeutics SA

8.10.1.     Business Overview

8.10.2.     Service Portfolio

8.10.3.     Strategic Developments

8.10.4.     Financial Overview

8.11.  Hikma Pharmaceuticals plc

8.11.1.     Business Overview

8.11.2.     Service Portfolio

8.11.3.     Strategic Developments

8.11.4.     Financial Overview

8.12.  Teva Pharmaceutical Industries Ltd.

8.12.1.     Business Overview

8.12.2.     Service Portfolio

8.12.3.     Strategic Developments

8.12.4.     Financial Overview

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources
  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources
  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2027)
  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*